Akero Therapeutics Inc.

37.65
0.21 (0.56%)
At close: Apr 17, 2025, 3:59 PM
37.63
-0.05%
After-hours: Apr 17, 2025, 04:20 PM EDT
0.56%
Created with Highcharts 11.4.39 AM4 PM10 AM12 PM1 PM2 PM3738
Bid 31
Market Cap 3B
Revenue (ttm) n/a
Net Income (ttm) -252.06M
EPS (ttm) -3.75
PE Ratio (ttm) -10.04
Forward PE -8.22
Analyst Strong Buy
Ask 42.72
Volume 414,825
Avg. Volume (20D) 1,437,863
Open 37.17
Previous Close 37.44
Day's Range 36.70 - 37.76
52-Week Range 17.86 - 58.40
Beta -0.18

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 63
Stock Exchange NASDAQ
Ticker Symbol AKRO
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $75, which is an increase of 99.20% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy0246
Price Target: $75
(99.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts
2 months ago
+97.52%
Akero Therapeutics shares are trading higher after... Unlock content with Pro Subscription